Larimar Therapeutics (NASDAQ:LRMR) Raised to “Sell” at Wall Street Zen

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Sunday, Wall Street Zen reports.

A number of other research firms have also weighed in on LRMR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, October 15th. Wedbush reduced their price objective on shares of Larimar Therapeutics from $11.00 to $9.00 and set an “outperform” rating for the company in a research note on Monday, November 16th. Finally, Leerink Partners started coverage on shares of Larimar Therapeutics in a research report on Monday, September 14th. They set an “outperform” rating and a $13.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $10.00.

Check Out Our Latest Analysis on LRMR

Larimar Therapeutics Stock Down 2.5%

LRMR stock opened at $3.14 on Friday. Larimar Therapeutics has a twelve month low of $1.91 and a twelve month high of $6.42. The stock has a market cap of $328.57 million, a P/E ratio of -1.93 and a beta of 0.73. The business’s 50-day moving average price is $2.85 and its 200-day moving average price is $3.75.

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) last released its earnings results on Monday, November 16th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.06. On average, equities research analysts expect that Larimar Therapeutics will post -1.30 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Larimar Therapeutics news, CFO Michael Celano bought 18,460 shares of the business’s stock in a transaction that occurred on Wednesday, November 11th. The stock was purchased at an average price of $2.71 per share, for a total transaction of $50,026.60. Following the completion of the transaction, the chief financial officer owned 234,245 shares of the company’s stock, valued at $634,803.95. This trade represents a 8.55% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO John B. Jr. Harlow bought 17,800 shares of the firm’s stock in a transaction that occurred on Wednesday, November 11th. The shares were acquired at an average cost of $2.80 per share, for a total transaction of $49,840.00. Following the purchase, the chief operating officer directly owned 67,800 shares in the company, valued at $189,840. This trade represents a 35.60% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders bought 144,132 shares of company stock worth $391,954. 4.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Larimar Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of LRMR. Ghisallo Capital Management LLC purchased a new position in shares of Larimar Therapeutics in the third quarter worth $2,396,000. Fi3 FINANCIAL ADVISORS LLC boosted its position in shares of Larimar Therapeutics by 1,249.6% during the third quarter. Fi3 FINANCIAL ADVISORS LLC now owns 39,342 shares of the company’s stock worth $126,000 after acquiring an additional 36,427 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Larimar Therapeutics by 61.2% during the third quarter. Goldman Sachs Group Inc. now owns 2,971,385 shares of the company’s stock valued at $9,494,000 after acquiring an additional 1,128,475 shares in the last quarter. Marshall Wace LLP grew its stake in Larimar Therapeutics by 9.1% during the third quarter. Marshall Wace LLP now owns 2,195,954 shares of the company’s stock valued at $7,005,000 after acquiring an additional 183,496 shares in the last quarter. Finally, Empowered Funds LLC purchased a new position in Larimar Therapeutics during the third quarter valued at $268,000. Institutional investors own 91.92% of the company’s stock.

About Larimar Therapeutics

(Get Free Report)

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.

See Also

Analyst Recommendations for Larimar Therapeutics (NASDAQ:LRMR)

Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.